News | Hemodynamic Support Devices | November 02, 2015

Miracor’s PiCSO Impulse System Highlighted at TCT 2015

Device may offer improved heart attack outcomes as novel therapy for cardioprotected PCI in the future

Miracor, PiCSO Impulse System, TCT 2015, cardioprotection during PCI, acute myocardial infarction

November 2, 2015 — Miracor Medical Systems GmbH announced that its PiCSO system was highlighted during the 2015 Transcatheter Cardiovascular Therapeutics (TCT) conference in San as offering new hope for cardioprotection during percutaneous coronary intervention (PCI).

Myocardial salvage and the need for cardioprotection for patients with acute myocardial infarction (AMI) was a focus topic at the conference.

“Despite recent improvements in the treatment of AMI, including shortened door-to-balloon times and advanced pharmacological strategies, survival has plateaued, and novel strategies are needed to reduce infarct size and improve clinical outcomes, especially in patients with large ST-segment elevation MI (STEMI),” stated Gregg W. Stone, M.D., professor of medicine at Columbia University College and director of cardiovascular research and education at the New York-Presbyterian Hospital Center for Interventional Vascular Therapies, during a symposium on novel strategies in PCI with focus on PiCSO Therapy. “In recent years, many approaches to improve reperfusion success and myocardial salvage have failed. Emerging data suggests that the effective delivery of PICSO improves myocardial perfusion and may reduce infarct size in STEMI patients,” he continued.

PiCSO is applied during the stenting procedure, directly following flow restoration, and increases myocardial perfusion and microcirculation, thereby preventing so-called reperfusion injury — damage to the myocardium caused by the stenting procedure itself.

“Further therapies to protect my patients — especially during complex PCI procedures — are needed. At San Raffaele Hospital, we have used PiCSO in elective, as well as acute, high-risk PCI procedures and are pleased to see that PiCSO can be applied without significant interruption of our standard workflows and without increasing the risk for the patient,” said Antonio Colombo, M.D., director of cardiovascular interventions at San Raffaele Scientific Institute, Columbus Hospital in Milan, Italy. “Once the PiCSO catheter is placed in the coronary sinus and connected to the PiCSO console, therapy is applied fully automatically so that I can focus on the stenting procedure, knowing that the patient’s heart is protected by PiCSO.”

For more information: www.miracormedical.com

Related Content

Videos | TCT | November 15, 2017
DAIC Editor Dave Fornell shows some of the innovations displayed on the expo floor at the 2017 Transcatheter Cardiova
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | TCT | November 09, 2017
November 9, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has select
Key Interventional Cardiology and structural heart Technologies to Prepare for TCT 2017.
Feature | TCT | October 26, 2017 | Dave Fornell
Here is an aggregation of DAIC content for all major cardiovascular technology news and advances this past year. These...
Videos | TCT | November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies
Videos | TCT | November 05, 2015
DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies pr
Videos | TCT | November 05, 2015
Tom Watson, clinical analyst for MDBuyLine, and DAIC Dave Fornell discuss some of the technology trends at the 2015 T
Amaranth Fortitute Bioresorbable stent

The Amaranth Fortitute bioresorbable stent was among several fully bioresorbing platforms discussed in sessions, late breaking trial data presentations and on the expo floor at TCT 2015.

Feature | TCT | October 19, 2015 | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline
There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) ann
Overlay Init